Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-ErbA yields a chromatin infrastructure-dependent transcriptional repression pathway

Transcriptional repression by nuclear hormone receptors is thought to result from a unison of targeting chromatin modification and disabling the basal transcriptional machinery. We used Xenopus oocytes to compare silencing effected by the thyroid hormone receptor (TR) and its mutated version, the on...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The EMBO journal 2000-08, Vol.19 (15), p.4074-4090
Hauptverfasser: Urnov, Fyodor D., Yee, Janet, Sachs, Laurent, Collingwood, Trevor N., Bauer, Anton, Beug, Hartmut, Shi, Yun-Bo, Wolffe, Alan P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Transcriptional repression by nuclear hormone receptors is thought to result from a unison of targeting chromatin modification and disabling the basal transcriptional machinery. We used Xenopus oocytes to compare silencing effected by the thyroid hormone receptor (TR) and its mutated version, the oncoprotein v‐ErbA, on partly and fully chromatinized TR‐responsive templates in vivo . Repression by v‐ErbA was not as efficient as that mediated by TR, was significantly more sensitive to histone deacetylase (HDAC) inhibitor treatment and, unlike TR, v‐ErbA required mature chromatin to effect repression. We find that both v‐ErbA and TR can recruit the corepressor N‐CoR, but, in contrast to existing models, show a concomitant enrichment for HDAC3 that occurs without an association with Sin3, HDAC1/RPD3, Mi‐2 or HDAC5. We propose a requirement for chromatin infrastructure in N‐CoR/HDAC3‐effected repression and suggest that the inability of v‐ErbA to silence on partly chromatinized templates may stem from its impaired capacity to interfere with basal transcriptional machinery function. In support of this notion, we find v‐ErbA to be less competent than TR for binding to TFIIB in vitro and in vivo .
ISSN:0261-4189
1460-2075
DOI:10.1093/emboj/19.15.4074